{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:15:51Z","timestamp":1788542151637,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04302-5","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:23:55Z","timestamp":1771053835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Pratik S.","family":"Bhojnagarwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devivasha","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Perales-Puchalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan Y.","family":"Sardesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"4302_CR1","unstructured":"(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89"},{"key":"4302_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0480-8","author":"P Ghione","year":"2018","unstructured":"Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M (2018) Novel immunotherapies for T-cell lymphoma and leukemia. Curr Hematol Malignancy Rep. https:\/\/doi.org\/10.1007\/s11899-018-0480-8","journal-title":"Curr Hematol Malignancy Rep"},{"key":"4302_CR3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21589","author":"E Marchi","year":"2019","unstructured":"Marchi E, O\u2019Connor OA (2019) The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21589","journal-title":"CA Cancer J Clin"},{"key":"4302_CR4","unstructured":"Swerdlow S, Campo E, Harris N et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. In: International Agency for Research on Cancer (Lyon, 2017)"},{"key":"4302_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. https:\/\/doi.org\/10.1001\/archderm.139.7.857","journal-title":"Arch Dermatol"},{"key":"4302_CR6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS et al (2018) The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2017.186577","journal-title":"Haematologica"},{"key":"4302_CR7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMct1114348","volume":"66","author":"DG Maloney","year":"2012","unstructured":"Maloney DG (2012) Anti-CD20 antibody therapy for B-cell lymphomas. The New Engl J Med 66:2008\u20132016","journal-title":"The New Engl J Med"},{"key":"4302_CR8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science (New York, NY) 359:1361\u20131365","journal-title":"Science (New York, NY)"},{"key":"4302_CR9","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2010.33.4623","volume":"29","author":"J Brody","year":"2011","unstructured":"Brody J, Kohrt H, Marabelle A, Levy R (2011) Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol 29:1864\u20131875","journal-title":"J Clin Oncol"},{"key":"4302_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68\u201383","journal-title":"Blood"},{"key":"4302_CR11","unstructured":"Murray D, Eldershaw SA, Pearce H, Davies N, McMurray J, Scarisbrick JJ, et al (2017) T cell versus T cell; a study of the immune checkpoint landscape in cutaneous T cell lymphoma. Blood 130"},{"key":"4302_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158035","author":"C-G Kim","year":"2021","unstructured":"Kim C-G, Sang Y-B, Lee J-H, Chon H-J (2021) Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22158035","journal-title":"Int J Mol Sci"},{"key":"4302_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.008","author":"PS Bhojnagarwala","year":"2025","unstructured":"Bhojnagarwala PS, Jose J, Zhao S, Weiner DB (2025) DNA-based immunotherapy for cancer: in vivo approaches for recalcitrant targets. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.008","journal-title":"Mol Ther"},{"key":"4302_CR14","first-page":"299","volume":"116","author":"D Jung","year":"2004","unstructured":"Jung D, Alt FW (2004) Unraveling V(D). J Recomb Cell 116:299\u2013311","journal-title":"J Recomb Cell"},{"key":"4302_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36853-8","author":"C Schleiss","year":"2019","unstructured":"Schleiss C, Ilias W, Tahar O, G\u00fcler Y, Miguet L, Mayeur-Rousse C, Mauvieux L, Fornecker LM, Toussaint E, Herbrecht R et al (2019) BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-36853-8","journal-title":"Sci Rep"},{"key":"4302_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<304::AID-IJC3>3.0.CO;2-Z","volume":"76","author":"CL Berger","year":"1998","unstructured":"Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL (1998) TUMOR-SPECIFIC PEPTIDES IN CUTANEOUS T-CELL LYMPHOMA: ASSOCIATION WITH CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX AND POSSIBLE DERIVATION FROM THE CLONOTYPIC T-CELL RECEPTOR. Int J Cancer 76:304\u2013311","journal-title":"Int J Cancer"},{"key":"4302_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","volume":"133","author":"MS Khodadoust","year":"2019","unstructured":"Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA (2019) B-cell lymphomas present immunoglobulin neoantigens. Blood 133:878\u2013881","journal-title":"Blood"},{"key":"4302_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nature21433","volume":"543","author":"MS Khodadoust","year":"2017","unstructured":"Khodadoust MS, Olsson N, Wagar LE, Haabeth OAW, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P et al (2017) Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543:723\u2013727","journal-title":"Nature"},{"key":"4302_CR19","doi-asserted-by":"crossref","unstructured":"Szymura SJ, Wang L, Zhang T, Cha S-c, Song J, Dong Z, Anderson A, Oh E, Lee V, Wang Z, et al (2024) Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun 15","DOI":"10.1038\/s41467-024-50880-2"},{"key":"4302_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0684-0","author":"ER Mardis","year":"2019","unstructured":"Mardis ER (2019) Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. Genome Med. https:\/\/doi.org\/10.1186\/s13073-019-0684-0","journal-title":"Genome Med"},{"key":"4302_CR21","doi-asserted-by":"crossref","unstructured":"Duperret EK, Perales-Puchalt A, Stoltz R, Hiranjith GH, Mandloi N, Barlow J, Chaudhuri A, Sardesai NY, Weiner DB (2019) A synthetic DNA, multi-neoantigen vaccine drives predominately MHC class I CD8+ T-cell responses, impacting tumor challenge. Cancer Immunol Res 7","DOI":"10.1158\/2326-6066.CIR-18-0283"},{"key":"4302_CR22","doi-asserted-by":"crossref","unstructured":"Vabret MB, Nicolas (2024) Alternative RNA splicing generates shared clonal neoantigens across different types of cancer. Nat Rev Immunol 24","DOI":"10.1038\/s41577-023-00986-3"},{"key":"4302_CR23","doi-asserted-by":"crossref","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L (2023) Neoantigens: promising targets for cancer therapy. Signal Trans Target Therapy 8","DOI":"10.1038\/s41392-022-01270-x"},{"key":"4302_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","volume":"65","author":"ENG Weiner","year":"2020","unstructured":"Weiner ENG, David B (2020) DNA vaccines: prime time is now. Curr Opin Immunol 65:21\u201327","journal-title":"Curr Opin Immunol"},{"key":"4302_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.04.005","author":"PS Bhojnagarwala","year":"2021","unstructured":"Bhojnagarwala PS, Perales-Puchalt A, Cooch N, Sardesai NY, Weiner DB (2021) A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation. Mol Ther. https:\/\/doi.org\/10.1016\/j.omto.2021.04.005","journal-title":"Mol Ther"},{"key":"4302_CR26","doi-asserted-by":"crossref","unstructured":"Bhojnagarwala P, Perales-Puchalt A, Gary E, Sardesai N, Weiner D (2022) Multi-epitope DNA vaccine targeting cancer neoantigens enhances efficacy of anti-PD1 therapy. JITC 10(Suppl 2)","DOI":"10.1136\/jitc-2022-SITC2022.1174"},{"key":"4302_CR27","doi-asserted-by":"crossref","unstructured":"Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesai NY, Lewis MG, Yan J, Weiner DB (2010) Systemic immunization with CCL27\/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine 28","DOI":"10.1016\/j.vaccine.2009.10.095"},{"key":"4302_CR28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.5.2912","author":"JI Sin","year":"1999","unstructured":"Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, McElhiney SP, Wolf MW, de Pompa- Bruin SJ, Higgins TJ, Ciccarelli RB, Weiner DB (1999) IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol. https:\/\/doi.org\/10.4049\/jimmunol.162.5.2912","journal-title":"J Immunol"},{"key":"4302_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.02.036","author":"LA Hirao","year":"2008","unstructured":"Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB (2008) Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2008.02.036","journal-title":"Vaccine"},{"key":"4302_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029231","author":"SA Kalams","year":"2012","unstructured":"Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J et al (2012) Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and\/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0029231","journal-title":"PLoS ONE"},{"key":"4302_CR31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G et al (2024) Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat Med 30:1044\u20131053","journal-title":"Nat Med"},{"key":"4302_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1086\/323395","volume":"184","author":"JS Yang","year":"2001","unstructured":"Yang JS, Kim JJ, Hwang D, Choo AY, Dang K, Maguire H, Kudchodkar S, Ramanathan MP, Weiner DB (2001) Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis 184:809\u2013816","journal-title":"J Infect Dis"},{"key":"4302_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.178572","author":"J Cheng","year":"2025","unstructured":"Cheng J, Hu X, Dai Z, Zeng Y, Jin J, Mu W et al (2025) Targeting intracellular LMP2 with costimulatory signal\u2013armed antibody-like TCR T cells. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.178572","journal-title":"JCI Insight"},{"key":"4302_CR34","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"E Letouz\u00e9","year":"2024","unstructured":"Letouz\u00e9 E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C (2024) Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv 8:2952\u20132959","journal-title":"Blood Adv"},{"key":"4302_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181596","author":"E Bartoszewska","year":"2024","unstructured":"Bartoszewska E, Tota M, Kisielewska M, Skowron I, Sebastianka K, Stefaniak O et al (2024) Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia. Cells. https:\/\/doi.org\/10.3390\/cells13181596","journal-title":"Cells"},{"key":"4302_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071040","author":"M Tusup","year":"2021","unstructured":"Tusup M, L\u00e4uchli S, Jarzebska NT, French LE, Chang Y-T, Vonow-Eisenring M, Su A, K\u00fcndig TM, Guenova E, Pascolo S (2021) mRNA-based anti-TCR CDR3 tumour vaccine for T-cell lymphoma. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13071040","journal-title":"Pharmaceutics"},{"key":"4302_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241273053","author":"A-R Jeong","year":"2024","unstructured":"Jeong A-R, Trando AH, Thomas SD, Riviere P, Sakowski PJ, Sokol ES, Goodman AM, Kurzrock R (2024) Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359241273053","journal-title":"Ther Adv Med Oncol"},{"key":"4302_CR38","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G et al (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood 101:4267\u20134272","journal-title":"Blood"},{"key":"4302_CR39","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.11.001","author":"L Karlin","year":"2014","unstructured":"Karlin L, Coiffier B (2014) The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.001","journal-title":"Semin Hematol"},{"key":"4302_CR40","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z et al (2017) Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 127:3462\u20133471","journal-title":"J Clin Invest"},{"key":"4302_CR41","doi-asserted-by":"crossref","unstructured":"Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, et al (2016) Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study. Blood 128","DOI":"10.1182\/blood.V128.22.181.181"},{"key":"4302_CR42","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M et al (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34:2698\u20132704","journal-title":"J Clin Oncol"},{"key":"4302_CR43","doi-asserted-by":"crossref","unstructured":"Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL (2018) PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety. Annals Hematol 97","DOI":"10.1007\/s00277-017-3127-2"},{"key":"4302_CR44","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B et al (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood 129:2437\u20132442","journal-title":"Blood"},{"key":"4302_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0559-7","author":"X Li","year":"2018","unstructured":"Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X et al (2018) Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-018-0559-7","journal-title":"J Hematol Oncol"},{"key":"4302_CR46","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1056\/NEJMc1803181","volume":"378","author":"L Ratner","year":"2018","unstructured":"Ratner L, Waldmann TA, Janakiram M, Brammer JE (2018) Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med 378:1947\u20131948","journal-title":"N Engl J Med"},{"key":"4302_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood-2011-05-355222","volume":"119","author":"YH Kim","year":"2012","unstructured":"Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ et al (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study. Blood 119:355\u2013363","journal-title":"Blood"},{"key":"4302_CR48","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","volume":"102","author":"T Maier","year":"2003","unstructured":"Maier T, Tun-Kyi A, Tassis A, Jungius K-P, Burg G, Dummer R, Frank FO (2003) Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102:2338\u20132344","journal-title":"Blood"},{"key":"4302_CR49","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao C-Y, Mahipal A, Shergill A, Spira AI et al (2024) A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med 30:1013\u20131022","journal-title":"Nat Med"},{"key":"4302_CR50","doi-asserted-by":"crossref","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 168","DOI":"10.1038\/s41586-023-06063-y"},{"key":"4302_CR51","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403:632\u2013644","journal-title":"Lancet"},{"key":"4302_CR52","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/2159-8290.CD-21-1207","volume":"12","author":"X Song","year":"2022","unstructured":"Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV (2022) Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma. Cancer Discov 12:1294\u20131313","journal-title":"Cancer Discov"},{"key":"4302_CR53","doi-asserted-by":"publisher","first-page":"7062","DOI":"10.4049\/jimmunol.173.11.7062","volume":"173","author":"M Gonthier","year":"2004","unstructured":"Gonthier M, Llobera R, Arnaud J, Rubin B (2004) Self-reactive T Cell Receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo. The J Immunol 173:7062\u20137069","journal-title":"The J Immunol"},{"key":"4302_CR54","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ (2011) T cell exhaustion. Nat Immunol 12:492\u2013499","journal-title":"Nat Immunol"},{"key":"4302_CR55","doi-asserted-by":"publisher","first-page":"61670","DOI":"10.18632\/oncotarget.11430","volume":"7","author":"L Li","year":"2016","unstructured":"Li L, Wan S, Tao K, Wang G, Zhao E (2016) KLRG1 restricts memory T cell antitumor immunity. Oncotarget 7:61670\u201361678","journal-title":"Oncotarget"},{"key":"4302_CR56","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbmt.2017.11.027","volume":"24","author":"TJA Hutten","year":"2018","unstructured":"Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Ml Kester JH, Frederik Falkenburg S, Berglund S, Luznik L, Jansen JH et al (2018) Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl 24:666\u2013677","journal-title":"Biol Blood Marrow Transpl"},{"key":"4302_CR57","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.ymthe.2020.02.018","volume":"28","author":"ND Shore","year":"2020","unstructured":"Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu Li, Sacchetta B et al (2020) CD8+ T cells impact rising PSA in biochemically relapsed cancer patients using immunotherapy targeting tumor-associated antigens. Mol Ther 28:1238\u20131250","journal-title":"Mol Ther"},{"key":"4302_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1940-6207.CAPR-22-0217","volume":"16","author":"JM Jacobson","year":"2023","unstructured":"Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I et al (2023) Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prevent Res (Philadelphia) 16:163\u2013173","journal-title":"Cancer Prevent Res (Philadelphia)"},{"key":"4302_CR59","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/infdis\/jit236","volume":"208","author":"SA Kalams","year":"2013","unstructured":"Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J et al (2013) Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 208:818\u2013829","journal-title":"J Infect Dis"},{"key":"4302_CR60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15","author":"RH Vonderheide","year":"2015","unstructured":"Vonderheide RH, Aggarwal C, Bajor DL, Goldenberg J, Loch C, Lee JC, Yan J, Morrow MP, DeMichele A, Langer CJ et al (2015) Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2015.33.15","journal-title":"J Clin Oncol"},{"key":"4302_CR61","doi-asserted-by":"crossref","unstructured":"Morrow MP, Gillespie E, Sylvester A, Amin MR, Belafsky PC, Best SR, Friedman AD, Klein AM, Lott DG, Mau T, et al (2025) DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107. Nat Commun 1518","DOI":"10.21203\/rs.3.rs-4770252\/v1"},{"key":"4302_CR62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00251-011-0579-8","volume":"64","author":"E Karosiene","year":"2012","unstructured":"Karosiene E, Lundegaard C, Lund O, Nielsen M (2012) NetMHCcons: a consensus method for the major histocompatibility complex class i predictions. Immunogenetics 64:177\u2013186","journal-title":"Immunogenetics"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04302-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:23:59Z","timestamp":1771053839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04302-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4302"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04302-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"APP, JY and NYS are employees of Geneos Therapeutics (APP is currently at JnJ). DBW has received grant funding, participates in industry collaborations, has received speaking honoraria, and has received fees for consulting, including serving on scientific review committees. Remunerations received by DBW include direct payments and equity\/options. DBW also discloses the following associations with commercial partners: Geneos (consultant\/advisory board), AstraZeneca (advisory board, speaker), Inovio (board of directors, consultant), Sanofi (advisory board), Pfizer (advisory board), and Advaccine (consultant). The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"80"}}